Compare BRAG & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRAG | TVRD |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5M | 36.8M |
| IPO Year | 2021 | N/A |
| Metric | BRAG | TVRD |
|---|---|---|
| Price | $1.67 | $3.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $6.00 | ★ $51.67 |
| AVG Volume (30 Days) | 36.4K | ★ 37.8K |
| Earning Date | 03-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.25 | N/A |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.46 | $3.15 |
| 52 Week High | $4.82 | $43.65 |
| Indicator | BRAG | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 43.56 | 35.03 |
| Support Level | $1.48 | N/A |
| Resistance Level | $2.22 | $4.52 |
| Average True Range (ATR) | 0.18 | 0.27 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 28.57 | 15.15 |
Bragg Gaming Group Inc is predominantly a B2B online gaming technology platform and casino content aggregator. The Company's proprietary studios offer high-performing, data-driven casino gaming titles from in-house brands Wild Streak, Spin, Atomic Slot Lab, Indigo Magic, and Oryx Gaming. It offers a full range of games including slot games, table games, card games, video bingo, scratch card games, virtual sports, and live dealer games which are featured on the company's PAM platform and also available for use on other gaming platforms offered by third parties. Geographically, the company generates a majority of its revenue from the Netherlands and the rest from Curacao, Malta, the United States, Croatia, and other regions.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.